Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy
01 mai 2023 13h20 HE
|
Avadel Pharmaceuticals plc
- Granted Orphan Drug Exclusivity through May 1, 2030 - -Advanced commercial preparations on track; LUMRYZ product availability expected in early June - - Final approval supported by robust efficacy...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
20 avr. 2023 16h05 HE
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, April 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Pharmaceuticals to Present at the 22nd Annual Needham Healthcare Conference
10 avr. 2023 08h00 HE
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, April 10, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03 avr. 2023 16h05 HE
|
Avadel Pharmaceuticals plc
DUBLIN, April 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee...
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
30 mars 2023 07h00 HE
|
Avadel Pharmaceuticals plc
• LUMRYZ™ NDA amendment filed March 1 requesting FDA final approval • Received FDA authorization to import LUMRYZ in advance of final approval decision; shortens timeline between potential approval...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 30
29 mars 2023 21h27 HE
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred Shares
29 mars 2023 21h24 HE
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced...
Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering of ADSs and Series B Preferred Shares
29 mars 2023 16h13 HE
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced...
Avadel Pharmaceuticals Enters into Royalty Agreement with RTW Investments for up to $75 Million
29 mars 2023 16h01 HE
|
Avadel Pharmaceuticals plc
– In parallel, extended maturity on $96.2 million of convertible notes to April 1, 2027 – Strategic financings strengthen the company’s balance sheet in advance of potential commercialization of...
Avadel Pharmaceuticals Announces FDA Authorization to Import Tentatively-Approved LUMRYZ™ Ahead of Anticipated Final Approval Decision
22 mars 2023 07h00 HE
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 22, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that...